Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
The DOI matches its Crossref record; 128 of the 132 references it cites were found in a registry or an index, and 4 are not checked yet.
Abstract
Vancomycin is a glycopeptide antibiotic that has been in clinical use for nearly 50 years as a penicillin alternative to treat penicillinase-producing strains of Staphylococcus aureus. It is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive infections involving methicillin-resistant S. aureus (MRSA).1 Early use of vancomycin was associated with a number of adverse effects, including infusion-related toxicities, nephrotoxicity, and possible ototoxicity. Upon further investigation, it appears that the impurities in early formulations of vancomycin caused many of these adverse events.1–4 Its overall use was curtailed significantly with the development of semisynthetic penicillins (e.g., methicillin, oxacillin, nafcillin) that were considered less toxic.1–4 However, the steady rise in the number of MRSA infections since the early 1980s has once again brought vancomycin into the forefront as the primary treatment for infections caused by this organism....
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Self-citationHundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Autoinduction and signal transduction in the regulation of staphylococcal virulence
Novick, R. P. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03526.x · Cited by 1,280 · cited 1×
“aureus that is responsible for orchestrating the expression of adherence factors, biofilm production, tolerance to vancomycin, and virulence factors.(66) The agr locus has been a subject of intense study because there appears to be a relationship between polymorphism in this gene cluster and patient response to vancom…”
BackgroundMartindale. The Extra Pharmacopoeia.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-5-687_2 · Cited by 1,111
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860 · cited 4×
“Hidayat et al.(53) prospectively investigated the efficacy and toxicity of adjusting vancomycin troughs to achieve an unbound concentration of at least four times the MIC.”
BackgroundInfluentialLevine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836 · cited 2×
“Sakoulas et al.(52) reported a significant correlation between vancomycin susceptibilities and patient outcome.”
BackgroundSelf-citation
Research works printed but not linked: 5
- Virgincar, 2004, Glycopeptides (dalabavancin, oritavancin, teicoplanin, vancomycin), 181
- Cooper, 1986, The development of vancomycin, 1
- Geraci, 1977, Vancomycin, Mayo Clin Proc, 52, 631
- Boffi El Amari, 2004, High versus standard dose vancomycin for osteomyelitis, Scand J Infect Dis., 36, 712
- Dangerfield, 1960, Clinical use of vancomycin, Antimicrob Agents Chemother, 61, 428
Cited by
Items 601–700 of 1,002
Continuous Infusion Vancomycin in Pediatric Patients: A Critical Review of the Evidence
Girand, H. L. (2020) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-25.3.198 · Cited by 24
Ellison, R. T., & Donowitz, G. R. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00069-2 · Cited by 34
“aureus pneumonia indicated that clinical cure correlates with a 24-hour area under the curve (AUC)/MIC ratio of greater than or equal to 400 and indicates that optimal dosing should target a vancomycin trough level of 15 to 20 μg/mL.(301,302) Unfortunately, even this high-level vancomycin therapy may not be effective…”
A fluorescence biosensor for therapeutic drug monitoring of vancomycin using in vivo microdialysis
Mu, F.-Y., Zhou, X., Fan, F., Chen, Z., & Shi, G. (2021) · Analytica Chimica Acta · doi:10.1016/j.aca.2021.338250 · Cited by 24
AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics
Jorgensen, S. C. J., Dersch‐Mills, D., Timberlake, K., Stewart, J. J., Gin, A. S., Dresser, L., & Dalton, B. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab048 · Cited by 30
Vancomycin Containing PLLA/β-TCP Controls MRSA In Vitro
Kankılıç, B., Bayramlı, E., Kılıç, E., Dağdeviren, S., & Korkusuz, F. (2011) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-011-2082-9 · Cited by 27
“PLLA and TCP have been combined [4] as a bone substitute; however, this composite has not been used for release of vancomycin to treat osteomyelitis arising from MRSA.”
BackgroundInfluentialTesfamariam, N. S., Aboelezz, A., & Mahmoud, S. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082317 · Cited by 27
“Furthermore, consistently maintaining low drug levels may increase the risk of MRSA resistance emergence, underscoring the crucial role of TDM for vancomycin to maximize its efficacy and decrease its nephrotoxicity [38].”
BackgroundStoessel, A. M., Hale, C. M., Seabury, R. W., Miller, C., & Steele, J. M. (2018) · Journal of Pharmacy Practice · doi:10.1177/0897190018764564 · Cited by 23
“Consensus guidelines from the American Society of Health-System Pharmacists, Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists, recommend troughs between 15 and 20 mg/L as a surrogate marker for achieving an AUC/MIC 400 in patients with deepseated MRSA infection due in part to…”
BackgroundInfluentialChantadee, T., Sawangsri, P., Santimaleeworagun, W., & Phaechamud, T. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.110761 · Cited by 23
Roydhouse, S., Carland, J. E., Debono, D. S., Baysari, M. T., Reuter, S. E., Staciwa, A. J., Sandhu, A., Day, R. O., & STOCKER, S. L. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14844 · Cited by 24
Miltenberg, B. H., Ludwick, L., Masood, R., Menendez, M. E., Moverman, M. A., Pagani, N. R., Puzzitiello, R. N., & Smith, E. L. (2022) · The Journal of Arthroplasty · doi:10.1016/j.arth.2022.10.023 · Cited by 23
Genome-Wide Association Study of Serum Creatinine Levels during Vancomycin Therapy
Driest, S. L. V., McGregor, T. L., Edwards, D. R. V., Saville, B., Kitchner, T., Hebbring, S. J., Brilliant, M. H., Jouni, H., Kullo, I. J., Creech, C. B., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127791 · Cited by 26
“[4] One adverse event associated with vancomycin use is nephrotoxicity, occurring in 3–19% of patients treated with conventional drug doses.”
BackgroundBue, M., Birke‐Sørensen, H., Thillemann, T. M., Hardlei, T. F., Søballé, K., & Tøttrup, M. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.06.014 · Cited by 23
Management of antibiotic-resistant infection in the newborn
Gray, J. W., & Patel, M. (2011) · Archives of Disease in Childhood Education & Practice · doi:10.1136/adc.2010.199653 · Cited by 23
Lenhard, J. R., Brown, T., Rybak, M. J., Meaney, C. J., Norgard, N. B., Bulman, Z. P., Brazeau, D. A., Gill, S. R., & Tsuji, B. T. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02657-15 · Cited by 25
“Unlike the AUC/MIC target of 400 (fAUC/MIC 200) advocated by current vancomycin guidelines, higher vancomycin exposures were needed to kill the CA-MRSA strains investigated in the present study (31).”
BackgroundSelf-citationPharmacokinetics of Vancomycin in Elderly Patients Aged over 80 Years
Bourguignon, L., Cazaubon, Y., Debeurme, G., Loue, C., Ducher, M., & Goutelle, S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00303-16 · Cited by 23
“The concentration-effect relationship of vancomycin has been characterized, and the pharmacokinetic (PK)-pharmacodynamic parameter that best describes the efficacy is the ratio of the area under the serum drug concentration-time curve to the MIC (AUC/MIC) (2, 3).”
BackgroundPloessl, C., White, C., & Manasco, K. B. (2015) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000817 · Cited by 23
“The pharmacodynamic profile of vancomycin and clinical practice guidelines recommend an area under the curve (AUC) of serum concentrations versus time over 24 hours to minimum inhibitory concentration (MIC) ratio ≥400 (AUC/MIC ≥ 400) for optimal clinical outcomes.(2,6) From adult data, trough vancomycin concentrations…”
BackgroundObara, V. Y., Zacas, C. P., Carrilho, C. M. D. D. M., & Delfino, V. D. A. (2016) · Revista Brasileira de Terapia Intensiva · doi:10.5935/0103-507x.20160071 · Cited by 31
“2016;28(4):380-386 Due to difficulties inherent in obtaining AUC/MIC (it is not feasible in clinical practice), the Infectious Diseases Society of America (ISDA), the American Society of Health-System Pharmacists, and the Infectious Diseases Society of Pharmacists suggest monitoring serum vanco trough levels (VTLs) to…”
MethodAssessment of initial vancomycin dosing in neonates
Dersch‐Mills, D., Bengry, T., Akierman, A., Alshaikh, B. N., & Yusuf, K. (2014) · Paediatrics & Child Health · doi:10.1093/pch/19.6.291 · Cited by 23
Fu, C.-F., Huang, J.-D., Wang, J., Lin, S., & Wu, C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193585 · Cited by 23
Achievement of Therapeutic Vancomycin Exposure With Continuous Infusion in Critically Ill Children*
Genuini, M., Oualha, M., Bouazza, N., Moulin, F., Tréluyer, J., Lesage, F., Renolleau, S., & Benaboud, S. (2018) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000001474 · Cited by 23
Hughes, D., Goswami, S., Keizer, R. J., Hughes, M. A., & Faldasz, J. D. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz444 · Cited by 23
STOCKER, S. L., Carland, J. E., Reuter, S. E., Stacy, A. E., Schaffer, A. L., Stefani, M., Lau, C., Kirubakaran, R., Yang, J. J., Shen, C. F. J., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2113 · Cited by 28
Muklewicz, J., Steuber, T. D., & Edwards, J. D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106234 · Cited by 23
The American College of Obstetricians and Gynecologists: WOMEN’S HEALTH CARE PHYSICIANS
(2019) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003334 · Cited by 43
Evaluation of a New Vancomycin Dosing Protocol in Morbidly Obese Patients
Kosmisky, D. E., Griffiths, C. L., Templin, M. A., Norton, J. H., & Martin, K. E. (2015) · Hospital Pharmacy · doi:10.1310/hpj5009-789 · Cited by 23
Deng, C., Liu, T., Wu, K., Wang, S., Li, L., Lu, H., Zhou, T., Cheng, D.-H., Zhong, X.-N., & Lu, W. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12092 · Cited by 23
“A consensus was reached in 2009 that therapeutic monitoring of vancomycin should be performed to prevent nephrotoxicity in prolonged therapy or in patients with unstable renal function.(2) The most useful index to monitor the efficacy of vancomycin is AUC/MIC.”
BackgroundInfluentialTreatment of Infections Caused By Antimicrobial-Resistant Gram-Positive Bacteria
Kinney, K. K. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181e99aa4 · Cited by 25
Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population
Jarkowski, A., Forrest, A., Sweeney, R. P., Tan, W., Segal, B. H., Almyroudis, N. G., Wang, E. S., & Wetzler, M. (2011) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155211402107 · Cited by 23
“Therapeutic trough concentrations universally accepted based upon new joint American Society of Health System Pharmacists/Infectious Diseases Society of America (ASHP/IDSA) guidelines are typically 10– 15mg/L.(5) Other medical conditions such as endocarditis, osteomyelitis, and pneumonia may require higher trough conc…”
MethodBalancing Vancomycin Efficacy and Nephrotoxicity: Should We Be Aiming for Trough or AUC/MIC?
Patel, K., Crumby, A. S., & Maples, H. D. (2015) · Pediatric Drugs · doi:10.1007/s40272-015-0117-5 · Cited by 23
Wininger, A. E., Gurusamy, P., Sullivan, T. C., Serpelloni, S., Taraballi, F., Park, K. J., & Brown, T. S. (2024) · The Journal of Arthroplasty · doi:10.1016/j.arth.2024.02.083 · Cited by 22
Bland, C. M., Porr, W. H., Davis, K. A., & Mansell, K. B. (2010) · Southern Medical Journal · doi:10.1097/smj.0b013e3181efb5b1 · Cited by 22
“Most of this data utilized manual testing to determine the MIC.”
MethodInfluentialA Moving Target—Vancomycin Therapeutic Monitoring
Burns, A. N., & Goldman, J. L. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa078 · Cited by 22
Moorthy, G. S., Downes, K. J., Vedar, C., & Zuppa, A. F. (2020) · Bioanalysis · doi:10.4155/bio-2020-0112 · Cited by 22
Zhong, L., Chen, D., Zhu, Y.-W., Jiang, Z., Cui, K., Zhang, S., & Chen, L. (2021) · Scientific Reports · doi:10.1038/s41598-021-82312-2 · Cited by 29
Vancomycin Associated Acute Kidney Injury: A Longitudinal Study in China
Pan, K., Can, C., Zhangzhang, C., Wu, W., Xu, Q., Ding, X., Xiaoyu, L., & Lv, Q. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.632107 · Cited by 22
“This was in contrast to trough concentrations exceeding 15 mg/L cited in American guidelines (Rybak et al., 2009; Ye et al., 2016).”
BackgroundTreatment of Drug-resistant Pneumococcal Meningitis
Hameed, N., & Tunkel, A. R. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0110-7 · Cited by 22
AUC Versus Peak–Trough Dosing of Vancomycin
Brown, D. L., Lalla, C. D., & Masselink, A. J. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31828b2a50 · Cited by 22
“AUC dosing has been increasingly promoted as an alternative vancomycin dosing method based on the fact that vancomycin is a non–concentration-dependent antibiotic.(1,9) Its bacterial killing does not depend on achieving high Cpeak levels.”
BackgroundInfluentialUse of Daptomycin in a Pregnant Patient with Staphylococcus aureus Endocarditis
Stroup, J. S., Wagner, J., & Badzinski, T. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m650 · Cited by 22
Saugel, B., Gramm, C., Wagner, J. Y., Messer, M., Lahmer, T., Meidert, A. S., Schmid, R. M., & Huber, W. (2013) · Journal of Critical Care · doi:10.1016/j.jcrc.2013.12.007 · Cited by 22
Evaluation of Vancomycin Prediction Methods Based on Estimated Creatinine Clearance or Trough Levels
Haeseker, M. B., Croes, S., Neef, C., Bruggeman, C. A., Stolk, L. M., & Verbon, A. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000250 · Cited by 22
“Another option to reduce TDM is proposed in the IDSA guidelines that recommend monitoring only trough plasma levels as the most practical method to monitor plasma vancomycin levels.(2) Furthermore, the IDSA guidelines suggest increasing the desired trough levels to 15–20 mg/L to obtain an increased target attainment o…”
BackgroundMethodInfluentialCao, Y., Yu, J., Chen, Y., Zhang, J., Wu, X., Zhang, Y., & Li, G. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3182a458bc · Cited by 22
Phillips‐Jones, M. K., Lithgo, R. M., Dinu, V. T., Gillis, R. B., Harding, J. E., Adams, G. G., & Harding, S. E. (2017) · Scientific Reports · doi:10.1038/s41598-017-12620-z · Cited by 22
Bue, M., Hanberg, P., Tøttrup, M., Thomassen, M. B., Birke‐Sørensen, H., Thillemann, T. M., Andersson, T. L., & Søballé, K. (2018) · Acta Orthopaedica · doi:10.1080/17453674.2018.1501548 · Cited by 22
“Higher and prolonged tissue concentrations cannot be achieved by means of increasing intravenous vancomycin doses as this is restricted by toxicity (Rybak et al. 2009).”
BackgroundStockmann, C. R., Olson, J. A., Rashid, J., Lubsch, L. M., Young, D. C., Hersh, A. L., Frymoyer, A. R., Ampofo, K., Liu, X., Wang, Y., et al. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1323 · Cited by 22
Shen, K., Yang, M., Fan, Y., Liang, X., Chen, Y., Wu, J., Yu, J., Zhang, H., Wang, R., Zhang, F., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy667 · Cited by 22
Reilly, A. M., Ding, M. X., Rower, J. E., & Kiser, T. H. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1392 · Cited by 22
Vancomycin Use in a Paediatric Intensive Care Unit of a Tertiary Care Hospital
Sridharan, K., Daylami, A. A., Ajjawi, R., & Ajooz, H. A. A. (2019) · Pediatric Drugs · doi:10.1007/s40272-019-00343-9 · Cited by 23
de Almeida, C. D. C., Silva, A. C. S. E., Oliveira, J. A. D. Q., Batista, I. S. F., Pereira, F. H., Gonçalves, J. E., Junior, V. A. N., & Martins, M. A. P. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222095 · Cited by 22
Chen, C., Li, M., Ma, L., Zhai, X., Luo, D., Zhou, Y. F., Liu, Z., & Cui, Y. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa150 · Cited by 22
Watanabe, E. M., Matsumoto, K., Ikawa, K., Yokoyama, Y., Shigemi, A., Enoki, Y., Umezaki, Y., Nakamura, K., Ueno, K., Terazono, H., et al. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.11.014 · Cited by 22
Initiator Types and the Causal Question of the Prevalent New-User Design: A Simulation Study
Webster‐Clark, M., Ross, R. K., & Lund, J. L. (2020) · American Journal of Epidemiology · doi:10.1093/aje/kwaa283 · Cited by 25
Imai, S., Kadomura, S., Miyai, T., Kashiwagi, H., Sato, Y., Sugawara, M., & Takekuma, Y. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15252 · Cited by 22
Ozaki, S., Saito, A., Nakaminami, H., Ōno, M., Noguchi, N., & Motomura, N. (2013) · Journal of Artificial Organs · doi:10.1007/s10047-013-0746-9 · Cited by 22
McCluggage, L. K., Lee, K., Potter, T. G., Dugger, R. W., & Pakyz, A. L. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080625 · Cited by 22
Norton, K., Ingram, P. R., Heath, C. H., & Manning, L. A. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt402 · Cited by 27
Suryadevara, M., Steidl, K. E., Probst, L. A., & Shaw, J. (2012) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-17.2.159 · Cited by 22
“America, and the Society of Infectious Disease Pharmacists.(1) These guidelines focused specifically on vancomycin TDM in adult patients.”
BackgroundInfluentialAlcalá‐Cerra, G., Paternina-Caicedo, Á. J., Moscote‐Salazar, L. R., Gutiérrez-Paternina, J. J., & Niño-Hernández, L. M. (2014) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recote.2014.04.001 · Cited by 21
Zasowski, E. J., Trinh, T. D., Atwan, S. M., Merzlyakova, M., Langf, A. M., Bhatia, S., & Rybak, M. J. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz079 · Cited by 21
“5%) had their vancomycin therapy dosed and monitored to a trough concentration target range of 15–20 mg/L, and the remaining had their vancomycin therapy dosed and monitored to an area under the curve (AUC) of 400– 600 mg*h/L [27, 28].”
Self-citationRetractedKim, H. W., Seok, Y. S., & Rhee, M. S. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz494 · Cited by 21
Suzuki, A., Hamada, Y., Ikeda, H., Tanaka, H., Yanagihara, M., Namiki, M., Watanabe, T., & Sasaki, T. (2020) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2020.10.014 · Cited by 21
Shu, L., Muheremu, A., Shoukeer, K., & Ji, Y. (2022) · World Neurosurgery · doi:10.1016/j.wneu.2022.12.066 · Cited by 21
Daptomycin for the treatment of acute bacterial meningitis: A narrative review
Jaber, R. H., & Beahm, N. P. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106770 · Cited by 21
Chang, J. H. T., Tasellari, A., Wagner, J. L., & Scheetz, M. H. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2275663 · Cited by 22
“Excretion occurs primarily via glomerular filtration, with 75% of a given dose excreted as unchanged drug in the urine [44,45].”
BackgroundInfluentialPharmacometrics in Bacterial Infections
Sy, S. K. B., & Derendorf, H. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4939-1304-6_8 · Cited by 23
Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients
Kim, D. I., Im, M. S., Choi, J. H., Lee, J., Choi, E. H., & Lee, H. J. (2010) · Korean Journal of Pediatrics · doi:10.3345/kjp.2010.53.12.1000 · Cited by 21
The effects of an electronic order set on vancomycin dosing in the ED
Hall, A. B., Montero, J., Cobian, J., & Regan, T. W. (2014) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2014.09.049 · Cited by 21
Evaluation of glycopeptide prescription and therapeutic drug monitoring at a university hospital
Roustit, M., François, P., Sellier, É., Roch, N., Vittoz, J.-P., Foroni, L., Stahl, J. ‐., & Pavèse, P. (2009) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365540903413614 · Cited by 21
“Yet, the inter-individual variability of glycopeptide pharmacokinetics makes it impossible to precisely predict the dosage needed to achieve therapeutic plasma concentrations at steady-state [11].”
InfluentialWalker, S. A. N., de Vijsel, L. M. V., Walker, S. E., Yamashita, S. K., Simor, A. E., & Hladunewich, M. (2010) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v63i3.915 · Cited by 24
“endocarditis, osteomyelitis, and hospital-acquired or ventilatorassociated pneumonia caused by Staphylococcus aureus.(9,10,12)”
BackgroundInfluentialMatson, K. L., Shaffer, C. L., Beck, G. L., & Simonsen, K. A. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1552 · Cited by 21
“The recommendation to achieve higher vancomycin trough concentrations stems from guidelines in 2009 that addressed rising MICs associated with MRSA and the need to optimize bacterial killing.(3) As a result, a number of researchers have investigated dosing required to achieve higher vancomycin target concentrations in…”
BackgroundEvaluation of Vancomycin Dosing and Corresponding Drug Concentrations in Pediatric Patients
Geerlof, L., & Boucher, J. (2014) · Hospital Pediatrics · doi:10.1542/hpeds.2014-0019 · Cited by 21
Maeda, M., Shoji, H., Shirakura, T., Takuma, T., Ugajin, K., Fukuchi, K., Niki, Y., & Ishino, K. (2016) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00255 · Cited by 24
Therapeutic drug monitoring – Key to personalized pharmacotherapy
Oellerich, M., Kanzow, P., & Walson, P. D. (2017) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2017.01.007 · Cited by 22
Peak Measurement for Vancomycin AUC Estimation in Obese Adults Improves Precision and Lowers Bias
Pai, M. P., Hong, J., & Krop, L. C. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02490-16 · Cited by 21
Ceftaroline for the treatment of methicillin-resistantStaphylococcus aureusbacteremia
White, B. P., Barber, K. E., & Stover, K. R. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160006 · Cited by 25
Liu, K.-S., Lee, C.-H., Lee, D., Liu, M., Tsai, F., & Tseng, Y. (2017) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2017.07.142 · Cited by 21
“However, there were several time points where the circulating vancomycin levels in the rabbits were greater than 15 mg/mL in that study, which raises concerns of potential nephrotoxicity.(26)”
BackgroundAbulfathi, A. A., Chirehwa, M., Rosenkranz, B., & Decloedt, E. H. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1254 · Cited by 22
Barriers and facilitators of appropriate vancomycin use: prescribing context is key
Chan, J. O. S., Baysari, M. T., Carland, J. E., Sandaradura, I., Moran, M., & Day, R. O. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2525-2 · Cited by 21
A clinical decision support system to improve adequate dosing of gentamicin and vancomycin
Pereboom, M., Mulder, I. J., Verweij, S. L., van der Hoeven, R. T. M., & Becker, M. L. (2019) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2019.01.002 · Cited by 21
Shingde, R., Graham, G. G., Reuter, S. E., Carland, J. E., Day, R. O., & STOCKER, S. L. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000690 · Cited by 22
“Male, % (n) 33 (2) 100 (4) 55 (6) 44 (4) 53 (16)”
Ahmed, A. A. M., Mekky, A. E. M., Elwahy, A. H. M., & Sanad, S. M. H. (2020) · Synthetic Communications · doi:10.1080/00397911.2019.1689269 · Cited by 21
Vitamin E in the prevention of vancomycin-induced nephrotoxicity
Badri, S., Soltani, R., Khorvash, F., Meidani, M., Alaei, S., & Taheri, S. (2020) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.283813 · Cited by 22
“This antibiotic plays a major role in the treatment of infections caused by methicillin-resistant Staphylococcus aureus (1).”
BackgroundCristinacce, A., Wright, J. G., Macpherson, M. P., Iaconis, J. P., & Das, S. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115292 · Cited by 21
Stewart, J. J., Jorgensen, S. C. J., Dresser, L., Lau, T. T. Y., Gin, A. S., Thirion, D. J. G., Nishi, C., & Dalton, B. (2021) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2020-0028 · Cited by 27
Antimicrobial dosing in critically ill patients with sepsis-induced acute kidney injury
Kumar, A., & Singh, N. P. (2015) · Indian Journal of Critical Care Medicine · doi:10.4103/0972-5229.151018 · Cited by 21
Thalakada, R., Legal, M., Lau, T. T. Y., Luey, T., Batterink, J., & Ensom, M. H. H. (2012) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v65i3.1140 · Cited by 21
Han, H. K., An, H., Shin, K.-H., Shin, D., Lee, S. H., Kim, J. H., Cho, S., Kang, H., Jang, I., Yu, K., et al. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000061 · Cited by 21
“aureus.(2,3) In use of vancomycin, therapeutic drug monitoring (TDM) is used to maximize efficacy and minimize nephrotoxicity in practice.”
Evaluation of a pediatric continuous-infusion vancomycin therapy guideline
McKamy, S., Chen, T. K., Lee, M., & Ambrose, P. J. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120072 · Cited by 21
Principles of Anti-infective Therapy
Pillai, S. K., Eliopoulos, G. M., & Moellering, R. C. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00018-7 · Cited by 26
Self-citationIshaq, H., Tariq, W., Talha, K. M., Palraj, R., Sohail, M. R., Baddour, L. M., & Mahmood, M. (2021) · Infection · doi:10.1007/s15010-020-01568-4 · Cited by 20
Glycopeptide antibiotic drug stability in aqueous solution
Jakaria, S. M., Budil, D. E., & Murtagh, J. (2022) · AAPS Open · doi:10.1186/s41120-022-00067-0 · Cited by 20
Cafaro, A., Barco, S., Pigliasco, F., Russo, C., Mariani, M., Mesini, A., Saffioti, C., Castagnola, E., & Cangemi, G. (2023) · Journal of Mass Spectrometry and Advances in the Clinical Lab · doi:10.1016/j.jmsacl.2023.12.003 · Cited by 20
Determining steady-state trough range in vancomycin drug dosing using machine learning
Tootooni, M. S., Barreto, E. F., Wutthisirisart, P., KASHANI, K. B., & Pasupathy, K. S. (2024) · Journal of Critical Care · doi:10.1016/j.jcrc.2024.154784 · Cited by 20
Prospective Trial of a Novel Nomogram to Achieve Updated Vancomycin Trough Concentrations
Wesner, A. R., Brackbill, M. L., Coyle, L. L., & Kidd, R. S. (2013) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2013/839456 · Cited by 20
“In 2009, the American Society of Health-System Pharmacists/Infectious Diseases Society of America/Society of Infectious Diseases Pharmacists published a consensus statement, updating the guidelines for appropriate vancomycin trough concentrations [2].”
BackgroundInfluentialSuzuki, Y., Tokimatsu, I., Morinaga, Y., Sato, Y., Takano, K., Kohno, K., Ogata, M., Hiramatsu, K., Itoh, H., & Kadota, J. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.11.027 · Cited by 22
Pharmacokinetics of antimicrobials in obese children
Sampson, M. R. (2013) · Generics and Biosimilars Initiative Journal · doi:10.5639/gabij.2013.0202.025 · Cited by 20
“Due to the lack of observed obesity effect on vancomycin PK, the two studies recommended the use of TBW for dosing of obese children, consistent with dosing recommendations in obese adults [55].”
Fukumori, S., Tsuji, Y., Mizoguchi, A., Kasai, H., Ishibashi, T., Iwamura, N., & To, H. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12399 · Cited by 20
“However, maintaining Ctrough in excess of 15 lg/mL was found to substantially increase the risk of a nephrotoxic event relative to when Ctrough 15 lg/mL. 17 Although clinical practice guidelines of the Infectious Diseases Society of America recommend a target AUC24/MIC, 5 it is difficult in the clinical setting to obt…”
MethodMurray, B. E., Arias, C. A., & Nannini, E. C. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00030-8 · Cited by 27
pharmacokinetics/pharmacodynamics; renal replacement therapy, continuous; antibiotics; antifungals
Honoré, P. M., Jacobs, R., Waele, E. D., & Spapen, H. D. (2017) · Anaesthesiology Intensive Therapy · doi:10.5603/ait.a2017.0071 · Cited by 20
“A target ratio ≥ 400 mg h-1L-1 was put forward to eradicate methicillin-resistant Staphylococcus aureus [18].”
BackgroundVancomycin dosing in critically ill trauma patients: The VANCTIC Study
Villanueva, R. D., Talledo, Ó., Neely, S. B., White, B. P., Celii, A. M., Cross, A. M., & Kennedy, R. O. (2019) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000002492 · Cited by 20
“Vancomycin troughs are currently recommended as surrogate markers for the AUC, with 15 mg/L to 20 mg/L being recommended for severe MRSA infections.(2) A meta-analysis of MRSA infections suggested lower rates of microbiological eradication for MRSA infections with a trough less than 15 mg/L without any effect on morta…”
BackgroundMethodInfluentialKanji, S., Roberts, J. A., Xie, J., Zelenitsky, S. A., Hiremath, S. S., Zhang, G., Watpool, I., Porteous, R., & Patel, R. V. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00817-6 · Cited by 20
Metadata
- Authors
- Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Albany Medical Center Hospital (US)
- University of Minnesota (US)
- Beth Israel Deaconess Medical Center (US)
- University of Wisconsin–Madison (US)
- New Orleans, LA
- Ochsner Health System (US)
- Division of General Internal Medicine, WSU
- Corresponding author
- Rybak, Michael
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-01
- Volume
- 66
- Issue
- 1
- Pages
- 82-98
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2133120422
- Semantic Scholar
- f97f86b0eb5acbf0d7b5f8d4197a9e67f28c94ab
- Cited by
- 1,795
- References
- 130
- Citations by year
- 2026: 41 · 2025: 63 · 2024: 60 · 2023: 72 · 2022: 94 · 2021: 110 · 2020: 135 · 2019: 129 · 2018: 123 · 2017: 113 · 2016: 104 · 2015: 120 · 2014: 122 · 2013: 119 · 2012: 120
- FWCI
- 61.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Health-System Pharmacy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, therapeutic drug monitoring, glycopeptides, methicillin-resistant Staphylococcus aureus, MRSA infection, Gram-positive bacterial infections, nephrotoxicity, ototoxicity, infusion-related toxicity, adverse drug reactions, pharmacokinetics, pharmacodynamics
- MeSH terms
- Adult, Anti-Bacterial Agents, Humans, Vancomycin, Drug Monitoring, Gram-Positive Bacterial Infections, Practice Guidelines as Topic, Vancomycin Resistance, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.